According to a new report by Quince Market Insights, the global migraine therapeutics market is estimated to be valued at US$ 7 billion in the year 2025, growing at a CAGR of 15.2% in the period 2016 to 2025.
Migraine is a complex debilitating neurological disorder which is often characterized by recurrent severe headaches in one side of the head. It is generally preceded by sensory warning signs and other symptoms such as sensitivity to light and noise, nausea, vomiting, dizziness, etc. It is one of the most common neurological disorders affecting more than 303 million people in the US alone. Even though the disease leads to huge economic burden, yet migraine remains under-recognized and under-treated. Depending upon the frequency and severity of headaches, there are various treatment options ranging from conventional medicines to supplements.
Conventional medicine for migraine treatment can be broadly divided into three categories – Abortive, Preventive and Complementary. Some of the common migraine drug classes include Triptan, Calcitonin Gene-Related Peptide (CGRP), Tezampanel, Acetylcholine Inhibitors/ Neurotoxins, and Ergots Alkaloids. Migraine treatment paradigm is dominated by Triptan drug classes.
Global migraine therapeutics market has been relatively stagnant over the past several years. Growth of the market is attributed to the prevalence of migraine and rising female population, as migraine is said to be one of the most common disorders affecting women. Moreover, other growth contributors to the market are patent expiration of leading drugs and stressed lifestyle. However, certain factors that are restraining growth of the market include poor efficacy of drugs, regulatory hurdles, the low diagnosis rate of migraine and preference for alternative therapies.
The report “Global Migraine Therapeutics Market [By Drug Classes – Triptan, CGRP, Acetylcholine Inhibitors/Neurotoxins, Others; By Region – North America (The US), Europe (The UK, Germany, France, Italy & Spain) and Asia Pacific (Japan) – Outlook 2025]” provides information on the current scenario, detailed market outlook of the global migraine therapeutics market with detailed analysis of major drug classes such as Triptan, CGRP, Acetylcholine Inhibitors/ Neurotoxins and other drug classes. The market is further analyzed with a detailed market outlook for global as well as regional markets such as North America, Europe, and the Asia Pacific. The analysis is provided for G7 nations. Future forecasts of Migraine treatment market overall and across various sub-segments has been provided till 2025, for all the geographies and all the drug classes. Furthermore, major industry players have been prudently analyzed in the competitive landscape section of the report in order to provide key comparative insights.
Major industry players operating in the global migraine therapeutics market include Eli Lilly & Company, Teva Pharmaceutical Industries, Alder Biopharmaceuticals, Amgen Inc., AbbVie Inc., Pfizer Inc., among others. These players are profiled herein based on attributes such as business overview, product segments, and financial analysis. It also compiles the performance comparison of the aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global as well as regional migraine market.
Key Factors Impacting Market Growth
- Prevalence of migraine
- Stressful Life
Regional Outlook:
North America, Western Europe, and Asia Pacific by region are estimated to dominate the migraine therapeutics market during the forecast period. These regions have been market leaders for the overall healthcare sector in terms of technological developments and advanced medical treatments. Moreover, the government policies have been favorable for the growth of the healthcare infrastructure in these regions. North America and Western Europe have an established healthcare infrastructure for product innovations and early adaptations. This is expected to drive the demand for migraine therapeutics market during the forecast period.
The US, Germany, France, UK, Canada, and Spain have been some the major markets in the region. Asia Pacific is estimated to register one of highest CAGR for migraine therapeutics market during the forecast period. This region has witnessed strategic investments by global companies to cater the growing demand in the recent years. China, Japan, India, South Korea, and Australia are amongst some of the key countries for migraine therapeuticsmarket in the region. Other regions including Middle East, Eastern Europe, and Rest of the World (South America and Africa) are estimated to be emerging markets for migraine therapeutics during the forecast period.
Companies Covered: Eli Lilly & Company, Teva Pharmaceutical Industries, Alder Biopharmaceuticals, Amgen Inc., AbbVie Inc., Pfizer Inc.
Market Segmentation:
By Drugs:
- Triptan
- CGRP
- Others
By Region:
- North America
- By Drugs
- Western Europe
- By Drugs
- Asia Pacific
- By Drugs
- Rest of the World
- By Drugs
Reasons To Buy This Report:
- Market size estimation of the Global Migraine Market on a regional and global basis
- The unique research design for market size estimation and forecast
- Profiling of major companies operating in the market with key developments
- Broad scope to cover all the possible segments helping every stakeholder in the market
Customization:
We provide customization of the study to meet specific requirements:
- By Segment
- By Sub-segment
- By Region/Country
For more information, contact: sales@quincemarketinsights.com